- Home
- MGN vs ATRA Comparison
MGN vs ATRA Comparison
Compare MGN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | ATRA |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MGN | ATRA |
|---|---|---|
| Price | $0.17 | $8.47 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ $3.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $3.92 |
| 52 Week High | $5.18 | $19.15 |
Technical Indicators
Market Signals| Indicator | MGN | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 68.54 |
| Support Level | $0.13 | $4.35 |
| Resistance Level | $0.36 | $13.14 |
| Average True Range (ATR) | 0.01 | 0.84 |
| MACD | 0.08 | 0.45 |
| Stochastic Oscillator | 37.38 | 50.94 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).